EGF receptor family: Twisting targets for improved cancer therapies

Antony W. Burgess, Yoav I. Henis, Nancy E. Hynes, Thomas Jovin, Alexander Levitzki, Ronit Pinkas-Kramarski, Yosef Yarden

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء


The epidermal growth factor receptor (EGFR) undergoes a conformational change in response to ligand binding. The ligand-induced changes in cell surface aggregation and mobility have a profound effect on the function of all the family members. Ligand also activates the EGFR intracellular kinase, stimulating proliferation and cell survival. The EGFR family are often activated, overexpressed or mutated in cancer cells and therapeutic drugs (including antibodies) can slow the progress of some cancers. This article provides a brief, annotated summary of the presentations and discussion which occurred at the Epidermal Growth Factor Receptor-Future Directions Conference held in Jerusalem in November 2013.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)74-81
عدد الصفحات8
دوريةGrowth Factors
مستوى الصوت32
رقم الإصدار2
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - أبريل 2014

All Science Journal Classification (ASJC) codes

  • !!Endocrinology
  • !!Clinical Biochemistry
  • !!Cell Biology


أدرس بدقة موضوعات البحث “EGF receptor family: Twisting targets for improved cancer therapies'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا